ALECENSA® (alectinib) 150mg
Product Overview
| Generic Name | ALECENSA® (alectinib) 150mg |
| Brand Name(s) | Alecensa® |
| Category | Antineoplastic / Cancer |
| Form | 240 Hard capsules; oral use |
| Strength | 150 mg |
| Therapeutic Class | Antineoplastic agent; kinase inhibitor (ALK inhibitor) |
| ATC Code | L01ED03 |
Manufacturing & Regulatory
| Manufacturer | Roche group / Genentech |
| GMP Compliance | WHO-GMP, EU-GMP |
| COFEPRIS | 010.000.6227.00 |
| Free Sale Certificate | must be requested from the manufacturer |
Logistics & Export
| MOQ | 5 units |
| Shelf Life | 60 months |
| Storage | Do not store above 30°C |
| Incoterms | EXW 30049049 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | For institutional supply, request batch CoA |
| SDS-Safety Data Sheet (PDF) | Genentech/Roche publishes an SDS for ALECENSA |
| CTD Summary (PDF) | CTD/eCTD Modules 2–5 are proprietary and normally not provided freely |
Special Notes
An oral ALK tyrosine kinase inhibitor used for adults with ALK-positive non-small cell lung cancer. It is indicated for metastatic ALK-positive NSCLC